Damora Therapeutics, Inc.

NASDAQ:DMRA

Biotechnology

Healthcare
$22.98 +0.34%

+$0.07 today

Market cap
$1.42B
Beta
1.48
P/E (TTM)
-0.1
EPS (TTM)
-$177.15
52W Low $2.45High $38.33

Volume 0.58M

Average 0.33M

DMRA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Damora Therapeutics, Inc.NASDAQ: DMRA

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $6.97M rose 262.6% year over year, ahead of the +63.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 71.2% from the prior quarter. Over 3 fiscal years it compounded at -8.2% a year.

Context

  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -6.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.97M+71.2% QoQ
Last fiscal yearDec 2025
$9.69M-6.1% YoY
LTMMar 2026
$14.73M+63.7% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+262.6%-100.0%-362.6 pp
1 year-6.1%-100.0%-93.9 pp
3-year CAGR-8.2%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
9.69M USD
Year-over-year change
-6.1%
4-year CAGR
-7.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How DMRA compares with its peers on the latest reported figures

  • DMRA's LTM Mar 2026 selling, general & admin of $14.73M is the 8th highest of the 9 companies compared; the peer median is $100.71M.
  • Its year-over-year change of +63.7% is the highest of 7, against a peer median of +10.9%.
  • Over three fiscal years its annual growth of -8.2% compares with a peer median of +11.2%.
DMRA Competitors Peer median
Selling, General & Admin for DMRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$1.4B +8.2%+11.2%24.0%
GMABGenmab A/SLTM Jun 2026$726.99M —-39.2%17.6%
GERNGeron CorporationLTM Mar 2026$154.66M -2.5%+54.0%78.9%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$118.84M +5.8%+1.0%39.6%
IRONDisc Medicine, Inc.LTM Sep 2026$82.59M +51.8%+67.0%—
QUREuniQure N.V.LTM Mar 2026$71.65M +50.0%+6.1%396.0%
KROSKeros Therapeutics, Inc.LTM Mar 2026$46.5M +13.6%+19.4%140.1%
DMRADamora Therapeutics, Inc.LTM Mar 2026$14.73M +63.7%-8.2%—
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025$10.49M ———
Peer median (excluding DMRA) $100.71M+10.9%+11.2%59.3%

Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue441K490K830K181K0
Gross Profit(441K)(490K)(830K)(181K)0
Gross Margin—————
Research & Development38.49M48.21M23.77M6.4M201.19M
Selling, General & Admin13.3M12.51M11.86M10.32M9.69M
Operating Expenses51.79M60.72M35.63M16.72M210.87M
Depreciation & Amortization441K490K830K181K34K
EBITDA(51.31M)(61.13M)(37.52M)(21.22M)(209.76M)
EBITDA Margin—————
Operating Income(52.23M)(61.21M)(36.46M)(16.9M)(210.87M)
Operating Margin—————
Interest Income156K722K1.69M844K1.17M
Interest Expense00000
Other Income / Expenses475K(417K)(1.89M)(4.5M)1.08M
Income Before Tax(51.75M)(61.62M)(38.35M)(21.4M)(209.79M)
Pre-Tax Margin—————
Income Tax Expense00041K50K
Net Income(51.75M)(61.62M)(38.35M)(21.44M)(209.84M)
Net Margin—————
EPS (Basic)(51.22)(60.63)(36.08)(18.53)(158.13)
EPS (Diluted)(51.22)(60.63)(36.08)(18.53)(158.13)
Weighted Avg Shares1.01M1.02M1.06M1.16M1.33M
Weighted Avg Shares (Diluted)1.01M1.02M1.06M1.16M1.33M

Damora Therapeutics, Inc.

NASDAQ:DMRA

Intrinsic Alpha fair value

Locked

Current Price

$22.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.